Insiders profit from FDA's Fast Track

A seven-month investigation by The Plain Dealer's Joel Rutchick and Brie Zeltner into the FDA's Fast Track drug review program has proven benefits to investors while doing little or nothing to speed up the availability of new medical treatments, compared to expedited review options that already existed before the drug industry lobbied to create Fast Track."Fast The news of Fast Track designation creates a boon for day traders, hedge funds and others looking to make quick money off biotech stocks." Securities information shows that stocks surge at the announcement of Fast Track designations, resulting in hefty profits for company insiders.